“No previous study has been able to quantify the local and systemic downstaging effects of systemic therapy in this manner and combine it with robust long-term follow-up data,” they noted.
This study was supported by the Swedish Research Council, the Swedish Cancer Society, and the National Institute of Health Research, Royal Marsden /Institute of Cancer Research Biomedical Research Center. Dr. Davies’ associates reported ties to Eli Lilly, Nestle, Astellas, Roche, Sanofi-Aventis, AstraZeneca, Amgen, Merck, Celgene, and Novartis.
By: MARY ANN MOON, Internal Medicine News Digital Network